Caution and clarity required in the use of chloroquine for COVID-19
- PMID: 32518920
- PMCID: PMC7270824
- DOI: 10.1016/S2665-9913(20)30093-X
Caution and clarity required in the use of chloroquine for COVID-19
References
-
- National Health Commission of the People's Republic of China Interpretation of COVID-19 treatment guidelines (6th version) Feb 19, 2020. http://www.gov.cn/zhengce/2020-02/19/content_5480958.htm (in Chinese).
-
- Riou B, Barriot P, Rimailho A, Baud FJ. Treatment of severe chloroquine poisoning. N Engl J Med. 1988;318:1–6. - PubMed
-
- Tanenbaum L. Antimalarial agents. Arch Dermatol. 1980;116:587. - PubMed
-
- Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Clin Pharmacokinet. 1996;31:257–274. - PubMed
-
- National Health Commission of the People's Republic of China Regarding dosage adjustments to the experimental use of chloroquine phosphate in the treatment of COVID-19. Feb 26, 2020. http://www.nhc.gov.cn/xcs/zhengcwj/202002/0293d017621941f6b2a48900352437... (in Chinese).
LinkOut - more resources
Full Text Sources